Department of Rheumatology and Internal Diseases, Poznan University of Medical Sciences, Poznan 61-545, Poland.
Institute of Human Genetics, Polish Academy of Sciences, Poznan 60-479, Poland.
J Immunol Res. 2020 Feb 3;2020:7509608. doi: 10.1155/2020/7509608. eCollection 2020.
Peroxisome proliferator-activated receptors () and beta-3-adrenergic receptors () are involved in the risk of hypertension. But their exact role in blood pressure modulation in patients with connective tissue diseases (CTD) is still not well defined. In this study, 104 patients with CTD and 103 gender- and age-matched controls were genotyped for Pro12Ala and C1431T polymorphisms of the gene and Trp64Arg polymorphism of the gene. Anthropometric and biochemical measurements were evaluated, followed by genotyping using TaqMan® SNP genotyping assays and polymerase chain reaction-restriction fragment length polymorphism. The prevalence of analyzed genotypes and alleles was comparable between patients with CTD and the control group, as well as hypertensive and normotensive subjects. Patients with CTD have lower body fat and higher body water amount, serum glucose, and triglyceride (TG) levels. Hypertensive subjects are older and have higher body mass, BMI, waist circumference (WC), body water content, glucose, and TG concentration. The multivariate analysis revealed that hypertensive subjects with Ala12/X or Trp64Trp have higher body mass and WC when compared to normotensive subjects. Trp64Trp polymorphism was also characterized by a higher TG level, while T1431/X subjects had higher WC. The presence of CTD, visceral fat distribution, and increased age are the predictors of hypertension development. Hypertensive patients with CTD and Trp64Trp polymorphism have an increased risk of visceral obesity development and metabolic complications, which in turn affects the value of blood pressure. In addition, either Ala12/X or T1431/X predicts the visceral body fat distribution in hypertensive subjects.
过氧化物酶体增殖物激活受体 () 和 β3-肾上腺素能受体 () 参与高血压的风险。但其在结缔组织疾病 (CTD) 患者血压调节中的确切作用仍未明确。本研究对 104 例 CTD 患者和 103 名性别和年龄匹配的对照者进行了基因分型,分析了 基因 Pro12Ala 和 C1431T 多态性及 基因 Trp64Arg 多态性。评估了人体测量学和生化指标,然后使用 TaqMan® SNP 基因分型检测和聚合酶链反应-限制性片段长度多态性进行基因分型。CTD 患者与对照组、高血压和血压正常患者的分析基因型和等位基因的患病率相似。CTD 患者体脂和体水含量、血清葡萄糖和甘油三酯 (TG) 水平较低。高血压患者年龄较大,体重、BMI、腰围 (WC)、体水含量、血糖和 TG 浓度较高。多变量分析显示,与血压正常者相比,Ala12/X 或 Trp64Trp 型高血压患者的体重和 WC 更高。Trp64Trp 多态性还表现为 TG 水平升高,而 T1431/X 患者的 WC 更高。CTD、内脏脂肪分布和年龄增加是高血压发展的预测因素。患有 CTD 的高血压患者和 Trp64Trp 多态性发生内脏肥胖和代谢并发症的风险增加,这反过来又影响血压值。此外,Ala12/X 或 T1431/X 预测高血压患者内脏体脂分布。